BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 21900401)

  • 1. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
    Guan B; Wang TL; Shih IeM
    Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice.
    Kartha N; Shen L; Maskin C; Wallace M; Schimenti JC
    Genetics; 2016 Aug; 203(4):1601-11. PubMed ID: 27280691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions.
    Guan B; Gao M; Wu CH; Wang TL; Shih IeM
    Neoplasia; 2012 Oct; 14(10):986-93. PubMed ID: 23097632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
    Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
    BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass spectrometric analysis of the phosphorylation levels of the SWI/SNF chromatin remodeling/tumor suppressor proteins ARID1A and Brg1 in ovarian clear cell adenocarcinoma cell lines.
    Kimura A; Arakawa N; Hirano H
    J Proteome Res; 2014 Nov; 13(11):4959-69. PubMed ID: 25083560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
    Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
    Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-regulation of transcription by BRG1 and BRM, two mutually exclusive SWI/SNF ATPase subunits.
    Raab JR; Runge JS; Spear CC; Magnuson T
    Epigenetics Chromatin; 2017 Dec; 10(1):62. PubMed ID: 29273066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II.
    Trizzino M; Barbieri E; Petracovici A; Wu S; Welsh SA; Owens TA; Licciulli S; Zhang R; Gardini A
    Cell Rep; 2018 Jun; 23(13):3933-3945. PubMed ID: 29949775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic
    Walter DM; Venancio OS; Buza EL; Tobias JW; Deshpande C; Gudiel AA; Kim-Kiselak C; Cicchini M; Yates TJ; Feldser DM
    Cancer Res; 2017 Apr; 77(7):1719-1729. PubMed ID: 28202515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
    BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activity of p53 is differentially regulated by Brm- and Brg1-containing SWI/SNF chromatin remodeling complexes.
    Xu Y; Zhang J; Chen X
    J Biol Chem; 2007 Dec; 282(52):37429-35. PubMed ID: 17938176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
    PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in
    Zundell JA; Fukumoto T; Lin J; Fatkhudinov N; Nacarelli T; Kossenkov AV; Liu Q; Cassel J; Hu CA; Wu S; Zhang R
    Cancer Res; 2021 Oct; 81(20):5325-5335. PubMed ID: 34548333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIC1 interacts with a specific subunit of SWI/SNF complexes, ARID1A/BAF250A.
    Van Rechem C; Boulay G; Leprince D
    Biochem Biophys Res Commun; 2009 Aug; 385(4):586-90. PubMed ID: 19486893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SWI/SNF inactivation in the endometrial epithelium leads to loss of epithelial integrity.
    Reske JJ; Wilson MR; Holladay J; Wegener M; Adams M; Chandler RL
    Hum Mol Genet; 2020 Dec; 29(20):3412-3430. PubMed ID: 33075803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
    Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The SWI/SNF complex and cancer.
    Reisman D; Glaros S; Thompson EA
    Oncogene; 2009 Apr; 28(14):1653-68. PubMed ID: 19234488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging roles of ARID1A in tumor suppression.
    Wu RC; Wang TL; Shih IeM
    Cancer Biol Ther; 2014 Jun; 15(6):655-64. PubMed ID: 24618703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
    Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
    Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.